3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Shares of HLB Pharma plunged almost 30% to 67,100 won on Friday to their daily price floors, as the US Food and Drug Administration (FDA) rejected a new drug approval for rivoceranib, the Korean firm’s liver cancer treatment, according to a Korea Times report. 18 May 2024
Precision oncology company Erasca, which is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, opened trading 8% higher Friday. 17 May 2024
The US Food and Drug Administration has approved Imdelltra (tarlatamab-dlle) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. 17 May 2024
Positive high-level results have been presented from the SUPERNOVA Phase III COVID-19 pre-exposure prophylaxis (prevention) trial of AstraZeneca’s sipavibart. 16 May 2024
Blackstone has announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug developer on immunology and inflammation. 16 May 2024
The USA’s House Committee on Oversight and Accountability held a markup meeting yesterday to consider a series of bills that address federal agency procurement of biotechnology equipment, safeguarding taxpayer dollars, improving federal cybersecurity, and more. 16 May 2024
USA and UK-based cancer cell therapy developer Adaptimmune Therapeutics has secured $125 million in financing, with the first tranche of $25 million available upon closing. 16 May 2024
The US Food and Drug Administration yesterday granted accelerated approval to Breyanzi (lisocabtagene maraleucel; liso-cel), from US pharma major Bristol Myers Squibb, for a new indication. 16 May 2024
Japanese drugmaker Eisai has started the rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Leqembi (lecanemab-irmb) subcutaneous (SC) autoinjector for weekly maintenance dosing. 15 May 2024
The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the supplemental Biologics License Application (sBLA) for Heplisav-B vaccine, said US immunotherapy specialist Dynavax Technologies. 15 May 2024
With the annual meeting of the American Society of Clinical Oncology (ASCO) now only weeks away, more drugmakers and research groups are lifting the lid on data they intend to present at the event. 14 May 2024
California, USA-based rare disease company Reneo Pharmaceuticals saw its shares fall 12.2% to $1.59 yesterday, when it announced it has entered into a definitive merger agreement with privately-held OnKure to combine the companies in an all-stock transaction. 14 May 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.